0053 SUVN-G3031: Safety, Tolerability and Pharmacokinetics of a Potent and Selective Histamine H3 Receptor Inverse Agonist - Single and Multiple Ascending Doses in Healthy Subjects

Nirogi Ramakrishna; Shinde Anil; Mudigonda Koteshwara; Bhyrapuneni Gopinadh; Muddana Nageswara Rao; Palacharla Raghava Chowdary; Ajjala Devender Reddy; Goyal Vinod Kumar; Ravula Jyothsna; Jetta Satish; Mohammed Abdul Rasheed

首页> 外文期刊>Sleep >0053 SUVN-G3031: Safety, Tolerability and Pharmacokinetics of a Potent and Selective Histamine H3 Receptor Inverse Agonist - Single and Multiple Ascending Doses in Healthy Subjects

【24h】

0053 SUVN-G3031: Safety, Tolerability and Pharmacokinetics of a Potent and Selective Histamine H3 Receptor Inverse Agonist - Single and Multiple Ascending Doses in Healthy Subjects

机译：0053 SUVN-G3031：有效和选择性的组胺H3受体逆激动剂的安全性，耐受性和药代动力学-健康受试者的单次和多次递增剂量

获取原文

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

IntroductionSUVN-G3031, potent and selective H3 receptor inverse agonist is being developed for the treatment of sleep related disorders. SUVN-G3031 modulates neurotransmitters involved in the maintenance of wakefulness and treatment of cataplexy. EEG in rodents produced wake promoting effects. Preclinical results provide a strong support for the potential therapeutic utility of SUVN-G3031 in sleep related disorders.

机译：简介SUVN-G3031是一种有效的选择性H3受体反向激动剂，正在开发中，用于治疗与睡眠有关的疾病。 SUVN-G3031调节与维持清醒和瘫痪症治疗有关的神经递质。啮齿动物的脑电图产生唤醒促进作用。临床前结果为SUVN-G3031在睡眠相关疾病中的潜在治疗效用提供了有力的支持。

著录项

来源
《Sleep 》 |2019年第1期| 共页
作者
Nirogi Ramakrishna; Shinde Anil; Mudigonda Koteshwara; Bhyrapuneni Gopinadh; Muddana Nageswara Rao; Palacharla Raghava Chowdary; Ajjala Devender Reddy; Goyal Vinod Kumar; Ravula Jyothsna; Jetta Satish; Mohammed Abdul Rasheed;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类人体生理学 ;
关键词

相似文献

外文文献
中文文献
专利

1. SUVN-G3031, A POTENT AND SELECTIVE HISTAMINE H3 RECEPTOR INVERSE AGONIST: SAFETY, TOLERABILITY AND PHARMACOKINETICS FOLLOWING SINGLE AND MULTIPLE ASCENDING DOSES IN HEALTHY ADULT SUBJECTS [J] . Bhyrapuneni G., Goyal V, Pandey S., Sleep . 2020 ,第Suppla1期

机译：SUVN-G3031，一种有效和选择性组胺H3受体反向激动剂：在健康成年对象中单一和多个上升剂量后的安全性，耐受性和药代动力学
2. Safety, Tolerability, and Pharmacokinetics of SUVN-G3031, a Novel Histamine-3 Receptor Inverse Agonist for the Treatment of Narcolepsy, in Healthy Human Subjects Following Single and Multiple Oral Doses [J] . Clinical drug investigation . 2020 ,第7期

机译：SUVN-G3031的安全性，耐受性和药代动力学，一种新的组胺-3受体反向激动剂，用于治疗鼻腔梗死，在单一和多剂量剂量之后
3. Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of ASP2408, a Potent Selective T-Cell Costimulation Modulator After Single and Multiple Ascending Doses in Healthy Volunteers and RA Patients [J] . Tong Zhu, James Keirns, Corrie Howieson, Clinical pharmacology in drug development . 2016 ,第5期

机译：ASP2408的药代动力学，药效动物，安全性和耐受性，在健康志愿者和RA患者中单一和多种上升剂量后的有效的选择性T细胞共抑制调节剂
4. Pharmacokinetics and Tolerability of Sublingual Fentanyl in Healthy Japanese and Caucasian Volunteers: Phase I, Open-Label Single-Dose Study [C] . U. Lorch, F. Farrell, J. Kilborn, International Pain Clinic Congress . 2008

机译：健康日本和白种人志愿者舌下芬太尼的药代动力学和耐受性：I期，开放标签单剂量研究
5. Safety tolerability pharmacokinetics and pharmacodynamics of PF-06650833 a selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor in single and multiple ascending dose randomized phase 1 studies in healthy subjects [O] . Spencer I. Danto, Negin Shojaee, Ravi Shankar P. Singh, 2019

机译：PF-06650833（一种选择性白介素-1受体相关激酶4（IRAK4）抑制剂）在健康受试者的单次和多次递增剂量随机1期研究中的安全性耐受性药代动力学和药效学
6. 0053 SUVN-G3031: Safety, Tolerability and Pharmacokinetics of a Potent and Selective Histamine H3 Receptor Inverse Agonist - Single and Multiple Ascending Doses in Healthy Subjects [O] . Ramakrishna Nirogi, Anil Shinde, Koteshwara Mudigonda, 2019

机译：0053 SUVN-G3031：有效和选择性组胺H3受体逆激动剂 - 单次和升高剂量的安全性，耐受性和药代动力学，在健康受试者中

0053 SUVN-G3031: Safety, Tolerability and Pharmacokinetics of a Potent and Selective Histamine H3 Receptor Inverse Agonist - Single and Multiple Ascending Doses in Healthy Subjects

摘要

著录项

相似文献

相关主题

期刊订阅